These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11293027)

  • 1. Demographic variables and microCog performance: relationships for VA patients under treatment for substance abuse.
    Lopez SJ; Ryan JJ; Sumerall SW; Lichtenberg JW; Glasnapp D; Krieshok TS; Van Fleet JN
    Psychol Rep; 2001 Feb; 88(1):183-8. PubMed ID: 11293027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
    Liraud F; Verdoux H
    Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor structure of MicroCog in a clinical sample.
    Lopez SJ; Sumerall SW; Ryan JJ
    Appl Neuropsychol; 2002; 9(3):183-6. PubMed ID: 12584084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demographic effects on the Trail Making Test in a drug abuse treatment sample.
    Horton AM; Roberts C
    Arch Clin Neuropsychol; 2003 Jan; 18(1):49-56. PubMed ID: 14591477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of demographic variables on neuropsychological test performance after traumatic brain injury.
    Sherrill-Pattison S; Donders J; Thompson E
    Clin Neuropsychol; 2000 Nov; 14(4):496-503. PubMed ID: 11262719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construct validity of the Babcock Story Recall Test.
    Horner MD; Teichner G; Kortte KB; Harvey RT
    Appl Neuropsychol; 2002; 9(2):114-6. PubMed ID: 12214822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing cognition following petrol sniffing for Indigenous Australians.
    Dingwall KM; Lewis MS; Maruff P; Cairney S
    Aust N Z J Psychiatry; 2010 Jul; 44(7):631-9. PubMed ID: 20560850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving treatment response of cognitively impaired veterans with neuropsychological rehabilitation.
    Grohman K; Fals-Stewart W; Donnelly K
    Brain Cogn; 2006 Mar; 60(2):203-4. PubMed ID: 16646121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Note on comparability of MicroCog test forms.
    Lopez SJ; Edwards LM; Floyd RK; Magyar-Moe J; Rehfeldt JD; Ryder JA
    Percept Mot Skills; 2001 Dec; 93(3):825-8. PubMed ID: 11806607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between cognitive testing performance and pattern of substance use in males at treatment entry.
    Schrimsher GW; Parker JD; Burke RS
    Clin Neuropsychol; 2007 May; 21(3):498-510. PubMed ID: 17455033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of onsite versus referral primary medical care for veterans in addictions treatment.
    Saxon AJ; Malte CA; Sloan KL; Baer JS; Calsyn DA; Nichol P; Chapko MK; Kivlahan DR
    Med Care; 2006 Apr; 44(4):334-42. PubMed ID: 16565634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between measures of inhibitory processes in patients with schizophrenia: role of substance abuse disorders.
    Jurado-Barba R; Morales-Muñoz I; Del Manzano BÁ; Fernández-Guinea S; Caballero M; Martínez-Gras I; Rubio-Valladolid G
    Psychiatry Res; 2011 Dec; 190(2-3):187-92. PubMed ID: 21704386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The detection of cognitive impairment among substance-abusing patients: the accuracy of the neuropsychological assessment battery-screening module.
    Grohman K; Fals-Stewart W
    Exp Clin Psychopharmacol; 2004 Aug; 12(3):200-7. PubMed ID: 15301637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of demographic factors on functional capacity and everyday functional outcomes in schizophrenia.
    Gould F; Bowie CR; Harvey PD
    J Clin Exp Neuropsychol; 2012; 34(5):467-75. PubMed ID: 22272559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frontal assessment battery (FAB) reveals neurocognitive dysfunction in substance-dependent individuals in distinct executive domains: Abstract reasoning, motor programming, and cognitive flexibility.
    Cunha PJ; Nicastri S; de Andrade AG; Bolla KI
    Addict Behav; 2010 Oct; 35(10):875-81. PubMed ID: 20584570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derived trail making test cutoffs and malingering among substance abusers.
    Horton AM; Roberts C
    Int J Neurosci; 2005 Jul; 115(7):1083-96. PubMed ID: 16051551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparability of neuropsychological test profiles in patients with chronic substance abuse and mild traumatic brain injury.
    Lange RT; Iverson GL; Franzen MD
    Clin Neuropsychol; 2008 Mar; 22(2):209-27. PubMed ID: 17853134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between substance use, neuropsychological functioning and treatment response in psychosis.
    deVille M; Baker A; Lewin TJ; Bucci S; Loughland C
    Psychiatry Res; 2011 Apr; 186(2-3):190-6. PubMed ID: 20843558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relation between ethnicity and cognistat performance in males seeking substance use disorder treatment.
    Schrimsher GW; O'Bryant SE; Parker JD; Burke RS
    J Clin Exp Neuropsychol; 2005 Oct; 27(7):873-85. PubMed ID: 16183620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.